Form 4: ImmunityBio CFO Sachs Reports RSU Vesting, Share Transactions

ImmunityBio's Chief Financial Officer, David C. Sachs, reported the vesting of restricted stock units and subsequent share transactions.

Summary

• David C. Sachs, Chief Financial Officer of ImmunityBio, Inc., reported transactions related to his beneficial ownership.
• On February 22, 2026, 40,650 restricted stock units (RSUs) vested, converting into common stock at a price of $0.
• Following the vesting, 20,682 shares of common stock were disposed of at a price of $8.7 per share, likely to cover tax obligations.
• After these transactions, Sachs directly owns 300,143 shares of common stock.
• The vesting commencement date for this RSU award was February 22, 2024, with a vesting schedule of 33.33% on the first and second anniversaries, and 33.34% on the third anniversary.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event, reflecting standard executive compensation practices rather than a significant change in company fundamentals or strategic direction.

Positives

• The vesting of 40,650 RSUs indicates a portion of the CFO's long-term incentive compensation has matured.
• The acquisition of shares at a $0 price reflects the conversion of RSUs into common stock, increasing direct ownership before tax-related sales.

Negatives

• The disposition of 20,682 shares at $8.7 per share reduces the CFO's direct beneficial ownership by that amount, likely for tax purposes.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that RSU vesting and subsequent 'sell to cover' transactions are standard practices for executive compensation in the biotechnology and pharmaceutical industries, aligning executive incentives with long-term company performance.

Comparison to Industry Standards

• The RSU vesting schedule, with annual installments over three years, is a common structure for executive equity awards across various industries, including biotech companies like Amgen or Gilead Sciences, designed to promote long-term retention and alignment with shareholder interests.
• The 'sell to cover' transaction for tax obligations upon RSU vesting is a standard procedure for executives, similar to practices observed at companies such as Pfizer or Moderna, ensuring compliance with tax laws without requiring executives to use personal funds for tax liabilities.

Stakeholder Impact

• Shareholders: The transaction is a routine part of executive compensation and does not directly impact company operations or financial performance. It reflects the ongoing alignment of executive incentives with company stock performance.
• Employees: No direct impact on general employees.

Next Steps

• Remaining unvested RSUs will continue to vest according to the schedule: 33.33% on the first and second anniversaries, and 33.34% on the third anniversary of the February 22, 2024 vesting commencement date.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction related to executive compensation (RSU vesting and tax-related share disposition). It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing itself does not present a catalyst for significant price movement or a re-evaluation of the company's fundamentals.

Keywords

ImmunityBio, IBRX, David C. Sachs, CFO, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Share Disposition, Executive Compensation